RU486 has been shown to lower SBP in the mineralocorticoid-salt model of hypertension.14 The GR may therefore contribute in part to the development of hypertension in DS/obese rats, and RU486 may act more effectively in the setting of increased plasma corticosterone levels. Here, NR3C1 is linked to Dravet syndrome.